RhumbLine Advisers’s Celularity CELU Stock Holding History

RhumbLine Advisers’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-189	Closed	-$591	–	4221
2024 Q2	$591	Hold	189	–	–	﹤0.01%	4280
2024 Q1	$988	Hold	189	–	–	﹤0.01%	4147
2023 Q4	$467	Hold	189	–	–	﹤0.01%	4202
2023 Q3	$420	Sell	189 -673	-78%	-$2.42K	﹤0.01%	4240
2023 Q2	$4.59K	Sell	862 -4,546	-84%	-$29.1K	﹤0.01%	4108
2023 Q1	$34K	Buy	5,408 +223	+4%	+$1.79K	﹤0.01%	2922
2022 Q4	$67K	Buy	5,185 +989	+24%	+$18.2K	﹤0.01%	2933
2022 Q3	$97K	Buy	4,196 +2,322	+124%	+$70.5K	﹤0.01%	3004
2022 Q2	$64K	Buy	+1,874	New	+$152K	﹤0.01%	3050

Other funds holding CELU

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $696M AUM 46.48% 1-Year Est. Return

RhumbLine Advisers's CELU Position: Q3 2024 in Review

RhumbLine Advisers sold out of Celularity (CELU) in Q3 2024, closing a stake of 189 shares — an estimated $591 sold.

RhumbLine Advisers first reported a position in CELU in Q2 2022 and held it in 9 quarters. The position peaked at $97K in Q3 2022. 27 funds tracked by Wall St. Rank hold CELU as of Q3 2024.

RhumbLine Advisers reported no remaining Celularity position as of Q3 2024 after selling out during the quarter.
RhumbLine Advisers sold 189 Celularity shares in Q3 2024, an estimated $591.
RhumbLine Advisers first reported a position in Celularity in Q2 2022 and held it in 9 quarters.
RhumbLine Advisers's Celularity position peaked at $97K in Q3 2022.
27 funds tracked by Wall St. Rank held Celularity as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.